Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.

Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.1739.2019. doi: 10.1158/1078-0432.CCR-19-1739. [Epub ahead of print]

PMID:
31558474
2.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

3.

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.

Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT.

Clin Cancer Res. 2014 Oct 1;20(19):5023-31. doi: 10.1158/1078-0432.CCR-14-0822. Epub 2014 Aug 8.

4.

Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.

Goldwirt L, Beccaria K, Carpentier A, Idbaih A, Schmitt C, Levasseur C, Labussiere M, Milane A, Farinotti R, Fernandez C.

J Neurooncol. 2015 Apr;122(2):273-81. doi: 10.1007/s11060-015-1717-1. Epub 2015 Jan 13.

PMID:
25794638
5.

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.

Carter TC, Medina-Flores R, Lawler BE.

Biomed Res Int. 2018 Dec 31;2018:6204676. doi: 10.1155/2018/6204676. eCollection 2018.

6.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):58-66. doi: 10.1016/j.ijrobp.2010.08.058. Epub 2010 Oct 30.

PMID:
21036490
7.

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM.

Clin Cancer Res. 2007 Jul 1;13(13):3942-50.

8.

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.

J Magn Reson Imaging. 2016 Nov;44(5):1229-1237. doi: 10.1002/jmri.25227. Epub 2016 Mar 12.

PMID:
26971534
9.

Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.

Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A.

Clin Transl Oncol. 2017 Jan;19(1):51-57. doi: 10.1007/s12094-016-1502-4. Epub 2016 Mar 30.

PMID:
27026567
10.

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Peters KB, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Desjardins A, Reardon DA, Friedman HS.

J Neurooncol. 2018 Apr;137(2):349-356. doi: 10.1007/s11060-017-2724-1. Epub 2017 Dec 21.

PMID:
29264836
11.

A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.

Norden AD, Korytowsky B, You M, Kim Le T, Dastani H, Bobiak S, Singh P.

J Manag Care Spec Pharm. 2019 Apr;25(4):428-436. doi: 10.18553/jmcp.2019.25.4.428.

12.

Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.

Navone SE, Guarnaccia L, Cordiglieri C, Crisà FM, Caroli M, Locatelli M, Schisano L, Rampini P, Miozzo M, La Verde N, Riboni L, Campanella R, Marfia G.

World Neurosurg. 2018 Dec;120:e380-e391. doi: 10.1016/j.wneu.2018.08.080. Epub 2018 Aug 23.

PMID:
30144594
13.

[68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide.

Provost C, Rozenblum-Beddok L, Nataf V, Merabtene F, Prignon A, Talbot JN.

Mol Imaging Biol. 2019 Apr;21(2):297-305. doi: 10.1007/s11307-018-1224-9.

PMID:
29948641
14.

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S.

J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3.

PMID:
26847813
15.

Influence of Bevacizumab on Blood-Brain Barrier Permeability and O-(2-18F-Fluoroethyl)-l-Tyrosine Uptake in Rat Gliomas.

Stegmayr C, Oliveira D, Niemietz N, Willuweit A, Lohmann P, Galldiks N, Shah NJ, Ermert J, Langen KJ.

J Nucl Med. 2017 May;58(5):700-705. doi: 10.2967/jnumed.116.187047. Epub 2017 Feb 2.

16.

Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography.

Chen H, Tong X, Lang L, Jacobson O, Yung BC, Yang X, Bai R, Kiesewetter DO, Ma Y, Wu H, Niu G, Chen X.

Theranostics. 2017 Jun 14;7(9):2363-2376. doi: 10.7150/thno.19898. eCollection 2017.

17.

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.

McCracken DJ, Celano EC, Voloschin AD, Read WL, Olson JJ.

J Neurooncol. 2016 Oct;130(1):193-201. Epub 2016 Aug 9.

PMID:
27502784
18.
19.
20.

Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.

Saito T, Sugiyama K, Ikawa F, Yamasaki F, Ishifuro M, Takayasu T, Nosaka R, Nishibuchi I, Muragaki Y, Kawamata T, Kurisu K.

World Neurosurg. 2017 Jan;97:21-26. doi: 10.1016/j.wneu.2016.09.072. Epub 2016 Sep 28.

PMID:
27693246

Supplemental Content

Support Center